You are here : Home > Funding & TTO > International > Europe

European & international partnerships

Europe

Horizon 2020


Involvement of the Institute of life sciences Frédéric Joliot in EU programmes.


Published on 8 June 2020



CEA contact:
Christophe Junot
DECISION
The H2020 DECISION project, funded to the tune of € 6 million, coordinated by AP-HP and in which Inserm, AP-HP and CEA (Joliot/DMTS/SPI) are participating, aims to better understand the pathophysiology of cirrhosis decompensation and to offer personalized medicine to patients with decompensated cirrhosis through the development of new diagnostic and prognostic tests and new combinations of treatments. For this, the partners (21 institutions) will analyze and integrate data of a multicenter cohort, model individual responses to treatments and identify new personalized therapeutic combinations. The SPI will conduct the metabolomic analyzes. DECISION, after MICROB-Predict, shows the commitment of EUROPE in the fight against cirrhosis, specifically decompensation of cirrhosis that can lead to death.
DECISION web site : https://decision-for-liver.eu/

Contacts:
Frédéric Dollé
Eric Hervieu

NOMATEN, same acronym for a European project (CSA teaming) and a center of excellence (CoE). NOMATEN is a support and coordination action (EC H2020 Teaming Phase 2 program, grant agreement 857470) aiming to accompany the NCBJ (National Center for Nuclear Research, Świerk, Poland)  in the construction and ramp-up of a center of excellence (CoE) of the same name, on innovative multifunctional materials for industrial and medical applications. http://nomaten.ncbj.gov.pl/


Contact:
Sophie Feuillastre

FLIX FLow chemistry for Isotopic eXchange
FLIX is a radically new concept for the ultimate-stage chemical isotopic labeling of high added-value molecules (drugs, biologics, smart materials) with stable isotopes (2H, 13C, 15N). It utilizes the unique properties of new generations of catalysts, which specifically and selectively exchange predetermined atoms and chemical motifs of end-use organic compounds. The ultimate outcome of the project is to devise and build a modular and adaptable flow chemistry system for the straightforward and combinable isotopic labeling of complex chemicals and biologics. The project is expected to have a multi-billion Euro positive impact on all sectors using stable isotopes in particular:
1) drug innovation, by accelerating preclinical studies, de-risking clinical trials and fostering the development of novel deuterated 'heavy drugs';
2) design of new tracers for diagnostic imaging with improved biological properties;
3) streamlining the production of multi-labeled complex molecules for NMR studies;
4) the development of novel isotopically enriched materials.

http://flix-h2020.eu/


Contact:
Christophe Junot

​MICROB-PREDICT
Microb-Predict aims to better understand the role of the microbiome in the evolution of cirrhosis of the liver and its interaction with drugs. This project is part of a personalized medicine approach for a better stratification of patients. The CEA/SPI will perform metabolomic analyzes.


Contact:
Edouard Duchesnay

​R-LINK

The R-LINK project aims to develop and validate a stratified approach to improve the care of patients suffering from bipolar disorders and treated with lithium. As a first step, our goal is to set up and exploit a multimodal database combining MRI, lithium-7 MRI, and blood "omic" biomarkers to define a predictive signature of the positive response to lithium. Our researchers are participating in this ambitious project because of their expertise in very high magnetic field imaging, statistics applied to biomedical research and multimodal database management. NeuroSpin's MRI 7T will be used to characterize the distribution of lithium in the human brain. These results will build a multidisciplinary network of international experts to define new diagnostic and therapeutic approaches to personalized medicine.






Contact:
Claude Comtat

​HYBRID

Imaging has become multimodal and multiparametric : it combines the benefits of multiple technologies to create new, more accurate images that carry more anatomical, molecular and functional information. This modern imaging makes it possible to better characterize the specificities of each patient and to evolve towards what is commonly called by the European Commission "Personalized Medicine". The optimal exploitation of the potential of this new imaging requires a new generation of experts trained in this integration of technologies: this is the goal of the innovative Hybrid training network that brings together a consortium of academic centers and industrial experts in multimodal imaging, from sensor design to image analysis in order to extract original biomarkers guiding personalized medicine.
More information at Hybrid website.



Contact:
Stéphanie Simon
EUROBIOTOX

Using current biotoxin best practices, members of the EuroBioTox consortium will develop and validate improved analytical tools, reagents and standard operating procedures based on realistic incident scenarios. Certified reference materials will be developed against this threat and, by establishing a European database, will be made available to the EuroBioTox network, comprising more than 50 European organizations.



Contact:
Franck Chauvat
ABACUS

ABACUS aims to develop a technology-oriented, business-oriented seaweed biorefinery, bringing to the market innovative seaweed-based ingredients for high-end applications ranging from seaweed terpenes for fragrance terpenoid long chain (carotenoids) for nutraceuticals and cosmetics.
https://www.abacus-bbi.eu/




logo_zikalliance.png


Contact:
Bernard Maillère
Laurent Bellanger
ZIKALLIANCE

ZIKAlliance, a multinational and multidisciplinary research consortium will study the clinical, fundamental, environmental and social aspects of Zika virus infection. In particular, ZIKAlliance will focus on the impact of Zika virus infection during pregnancy and the natural history of Zika virus in humans and their environment. In collaboration with two other consortia funded by the EC (ZikaPLAN and ZIKAction), ZIKAlliance will also work on the development of an intervention platform in Latin America and the Caribbean.



Contact:
Eric Doris
DIAMESTAR (EURONANOMED II)

The objective of DiamESTar is to evaluate the efficacy of a new siRNA / nanocarrier complex to treat metastatic tumors of Ewing's sarcoma (SE), when this complex is associated with a Fab antibody fragment directed against a membrane protein, overexpressed in the cells.


logo_se2b.png
Contact:
Diana Kirilovsky

SE2B

SE2B (Solar Energy into Biomass) will train 16 PhD students in cutting-edge innovations that constitute bio-economy. This ITN aims to understand how light reactions and photosynthesis are regulated, and thus optimally optimize the efficiency of the use of light. Program of which we are coordinator.


Logo_Isotopics.png
Contact:
Christophe Dugave

ISOTOPICS
ISOTOPICS, of which we are coordinators (SCBM), is an European project of the ITN type, which will train fifteen doctoral students as experts in isotopic marking. The development of new methods allowing the simple, rapid and specific introduction of several labeling molecules is crucial for the pharmaceutical industry strongly involved in this consortium. This strategic skill allows for more effective identification of drug candidates.



Contact:
Alexandre Vignaud